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Systematic review of studies investigating 
ventilator associated pneumonia diagnostics 
in intensive care
Basem Al‑Omari1,4* , Peter McMeekin2, A. Joy Allen3, Ahsan R. Akram4, Sara Graziadio3,5, Jana Suklan3, 
William S. Jones3, B. Clare Lendrem3, Amanda Winter6, Milo Cullinan7, Joanne Gray2, Kevin Dhaliwal4, 
Timothy S. Walsh8 and Thomas H. Craven4,8 
Abstract 
Background: Ventilator‑associated pneumonia (VAP) is an important diagnosis in critical care. VAP research is compli‑
cated by the lack of agreed diagnostic criteria and reference standard test criteria. Our aim was to review which refer‑
ence standard tests are used to evaluate novel index tests for suspected VAP.
Methods: We conducted a comprehensive search using electronic databases and hand reference checks. The 
Cochrane Library, MEDLINE, CINHAL, EMBASE, and web of science were searched from 2008 until November 2018. 
All terms related to VAP diagnostics in the intensive treatment unit were used to conduct the search. We adopted 
a checklist from the critical appraisal skills programme checklist for diagnostic studies to assess the quality of the 
included studies.
Results: We identified 2441 records, of which 178 were selected for full‑text review. Following methodological 
examination and quality assessment, 44 studies were included in narrative data synthesis. Thirty‑two (72.7%) studies 
utilised a sole microbiological reference standard; the remaining 12 studies utilised a composite reference standard, 
nine of which included a mandatory microbiological criterion. Histopathological criteria were optional in four studies 
but mandatory in none.
Conclusions: Nearly all reference standards for VAP used in diagnostic test research required some microbiological 
confirmation of infection, with BAL culture being the most common reference standard used.
Keywords: Ventilator‑associated pneumonia, Diagnostics, Intensive care, Critical care
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Take home message
1. This comprehensive systematic review assesses the 
reference standard tests used to evaluate novel index 
tests for suspected VAP in ICU over 10 years period 
(2008 until 2018) and included high-quality studies 
with low risk of bias.
2. BAL culture is the most common reference standard 
used for VAP diagnostic in ICU and almost all refer-
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Background
Ventilator-associated pneumonia (VAP) refers to inflam-
mation of the lung parenchyma caused by infectious 
agents acquired specifically while receiving invasive 
mechanical ventilation [1, 2]. VAP is a preventable noso-
comial complication which potentially contributes to 
avoidable mortality and morbidity [3, 4]. Therefore, it 
is considered a clinically and epidemiologically impor-
tant measure of the quality of care [5, 6]. It contributes 
to additional resource consumption, adding time and 
expense to an intensive care stay, accounting for a large 
proportion of all antibiotic prescriptions [7]. VAP is con-
sidered to be responsible for an additional cost of approx-
imately $40,000 per episode in the US [8, 9] and around 
£9000 in the UK [10]. The contribution of an episode 
of VAP to mortality is difficult to definitively ascertain 
because of the high number and severity of confounders 
amongst the at-risk population [4, 11–13]. This attribut-
able mortality has been reported from high to neutral or 
near-neutral [11–13].
Throughout recent decades investigators have not 
adopted a fixed set of criteria or a fixed definition for 
VAP [14]. This lack of a reference standard has led to 
an inability to make comparisons across study sets and 
uncertainty about VAP incidence [15]. The incidence of 
VAP varies widely in different studies depending on the 
diagnostic criteria used, type of intensive therapy unit 
(ITU), and patient population [16, 17].
Existing literature reports that the incidence of VAP 
varies widely between 4.0% and 28.8% of the at-risk pop-
ulation [8, 18–24], with an event rate between 1.4 and 
16.5 per 1000 ventilator days [1, 25–27]. As VAP rates 
have become an important quality indicator, the Centre 
for Disease Control and the European Centre for Disease 
Control use their own precise case definitions to identify 
VAP events [28, 29]. Both definitions return similar VAP 
rates making them adequate for surveillance purposes 
and benchmarking of critical care units internationally 
[1]. However, due to the lack of concordance between 
these two definitions, they do not make ideal reference 
standards [1, 28], and further highlight the difficulty in 
achieving consensus in diagnosing VAP. Microbiological 
samples, especially quantitative culture of bronchoal-
veolar lavage (BAL), are considered to be integral to the 
diagnosis of VAP [30, 31]. However, a systematic review 
of diagnostic methods in 2008 found that microbiologi-
cal methods did not contribute to the accuracy of diag-
nosis over clinical criteria and all respiratory sampling 
methods were equivalent [32]. The continuing lack of an 
agreed reference standard hampers research into novel 
diagnostic methods. The aim of this review was to iden-
tify what reference standards have been used in diagnos-
tic evaluation research for VAP.
Methods
The protocol for this review was published in PROS-
PERO (International Prospective Register of Systematic 
Reviews) under registration CRD42019125449 [33].
Search strategy
A comprehensive search strategy was developed by 
one of the authors (BA). The Cochrane Library, Pub-
Med (MEDLINE), CINHAL, EMBASE, and web of sci-
ence were electronically searched from January 2008 
until November 2018. We limited our search to stud-
ies published after 2008 following a comprehensive 
systematic review of diagnostic methods [32]. Medical 
Subject Headings (MeSH) and search terms were used 
to interrogate the databases. The 3 concepts used for 
the searches were VAP, diagnostics, and ITU (for search 
terms see Additional file  1). No restriction on publi-
cation language was applied. In addition, electronic 
searching of Google and hand searching through an 
examination of the reference list of the published arti-
cles were also used to identify additional publications 
(an example of MEDLINE search is provided in Addi-
tional file 1).
Review strategy
All records were independently reviewed by the lead 
author (BA) and another author (PM or JG) and disa-
greement was resolved by a third independent adjudi-
cator (PM or JG). Initially, titles and abstracts review 
of all records, then full-text reviews were conducted 
against the inclusion/exclusion criteria. Studies 
included in the review fulfilled the following criteria: 
(1) adult ventilated patients of any gender, (2) ITU set-
tings, (3) suspected VAP as defined in this study (after 
48  h on the ventilator), (4) focused on the diagnostic 
procedures of VAP (clinical markers, biomarkers, chest 
x-ray, chest ultrasound (U/S), lung biopsy, BAL and 
mini-BAL, protected specimen brush (PSB), blind PSB, 
Endotracheal Aspirate (ETA)). Studies were excluded 
from the review if they: (1) were animal studies, (2) 
included patients under the age of 18  years old, (3) 
focused on the surveillance of VAP, (4) compared the 
diagnosis of VAP against another illness diagnostic, (5) 
were feasibility studies, (6) included participants who 
were already diagnosed with VAP, (7) investigated VAP 
treatment effectiveness by monitoring biomarkers or 
other diagnostics, (8) evaluated risk factors to predict 
VAP, (9) were procedures used to predict the mortal-
ity in VAP, (10) were case-controlled studies. All papers 
that passed the full-text review and those that had 
some diagnostic technical terms were examined by an 
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ITU clinician (THC) to confirm their clinical relevance 
to the research question.
Quality assessment and data extraction
A team of 12 reviewers (systematic reviewers, clinicians, 
methodologists, health economists) from the Univer-
sity of Northumbria, Newcastle University, The New-
castle Upon Tyne Hospitals NHS Foundation Trust, and 
the University of Edinburgh were involved in the qual-
ity assessment and data extraction process. All included 
papers were quality assessed and the data were extracted 
by two authors independently. Any disagreement was 
discussed between both reviewers in the first instance. 
The further disagreement was resolved by a third 
reviewer. The quality assessment scoring checklist was 
adopted from the Critical Appraisal Skills Programme 
(CASP) checklist for diagnostic studies [34], which is 
one of the well-recognised methodological quality or 
risk of bias assessment tools for primary and secondary 
medical studies [35, 36] and has been used to assess the 
quality of diagnostic studies in systematic reviews [37–
39]. The quality assessment scoring checklist contains 
8 questions from the overall 12 questions in the CASP 
checklist. Questions from section C in the CASP for 
diagnostics checklist “will the results help locally?” were 
not included in our scoring as the main aim of the review 
was not related to the local application of the diagnostic 
procedures. Studies were assigned a score of ‘1’ for each 
item of the checklist if they were considered to meet the 
aspect of this item and ‘0’ if not. A total score for each 
study was calculated by summing the item scores. The 
maximum possible final score was 8. Any study that 
scored ‘0’ for the first or the second question or scored 
less than ‘5’ out of 8 in total was excluded. According to 
CASP guide for diagnostic studies, if the answer to ques-
tion 1 or 2 while critically appraising a study was “no”, 
then it is not worth continuing. That leaves 6 questions 
out of the total 8 we used in our quality assessment. Tak-
ing in consideration that these questions are equally as 
important but less important than the first 2 question, we 
determined that a study must fulfil the quality of at least 
half of these 6 points (score 3 out of 6) to be consider for 
the review. Therefore, this threshold was derived through 
reviewer consensus that studies scoring less than 5 out of 
8 were not of sufficient quality to adequately address the 
research question.
A standardised data extraction form was developed 
by three authors (AJA, BA, THC) and reviewed by all 
authors (for quality assessment and data extraction 
form see Additional file  2). We recorded and present 
study country of origin, study size, male: female ratio 
or enrolled participants, index test(s) under investiga-
tion, reference standard used to define VAP, and test 
characteristics. Although test characteristics for the 
index test are not relevant to the aims of this review, we 
present them herein because several of the index tests are 
also used as reference standards. Test characteristics are 
taken directly from the studies or calculated using data 
contained within the studies. Where multiple test char-
acteristics are presented in the original paper, we selected 
those highlighted by the original authors or those which 
reflect the comparison best, or those which indicate 
the best performance. Where BAL was conducted, we 
recorded the details of the lavage procedure.
A narrative data synthesis approach was used to report 
the results from reviewed studies. Due to the large vari-
ation in practice, processes, and reference standards, a 
meta-analysis of diagnostic accuracy was not conducted.
Results
Studies identified
The searches identified a total of 2441 articles. Records 
that were not published in English were translated to 
English using Google translator. 2263 articles were 
excluded on the basis of title and abstract and a further 
123 on the basis of full-text screening were excluded as 
not clinically relevant to the inclusion criteria or meeting 
at least one of the exclusion criteria, leaving 55 articles 
for quality assessment (see Fig. 1 for PRISMA flow chart).
Quality assessment and data extraction
Of the 55 studies examined in the quality assessment 
stage, 11 studies were excluded due to either scored ‘0’ 
for the first or the second question or scored less than 
‘5’ out of ’8’ in total score, leaving 44 studies included in 
this review [40–83]. All scored were agreed by at least 
two reviewers and reviewed by the principal investigator 
(PI). The lowest score assigned to any included study was 
‘5’ out of ‘8’. Three studies scored 8/8, 24 studies scored 
7/8, 11 studies scored 6/8, and six studies scored 5/8 (see 
Table 1).
As expected, all papers suffered from bias in their 
accuracy estimates of the index test from the use of 
an imperfect reference standard comparison, a well-
known issue with comparative diagnostic accuracy 
studies [84]. The results of the quality assessment 
reviews conducted using the form adopted from CASP 
diagnostic study checklist showed that five papers [51, 
54, 57, 62, 82] suffered from verification bias: not all 
patients received testing by both the index and the ref-
erence standard. In 38 papers [41–47, 49–53, 55–59, 
61–68, 70, 71, 73–82], the results of the index test could 
have been influenced by the reference standard result. 
This means that there was no evidence blinding or the 
tests being performed independently. The VAP status 
for all participants in the study was not clearly defined 
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in two papers [47, 65]. The methodology description 
was not described in detail in three papers [40, 45, 82] 
and the results of the study were not clearly presented 
in five papers [46, 64, 67, 69, 75]. There was a lack of 
certainty regarding the results of the study on 11 occa-
sions [40, 42, 43, 46, 58, 64, 65, 67, 68, 74, 75]. CASP 
diagnostic study checklist guide was followed in assess-
ing all points.
The disagreement was solved through discussion 
between both reviewers on 20 papers, and adjudication 
of a third reviewer in one paper. Forty-three of the stud-
ies were cohort studies (38 of which were prospective 
studies) and one was a secondary analysis of data from a 
randomised controlled trial (RCT) [57]. All studies were 
published between 2008 and 2018 with a wide geographi-
cal spread; four studies conducted in the UK [41, 44, 72, 
74], eight in the USA [40, 45, 47, 50, 56, 62, 67, 75], seven 
in France [51, 53, 55, 63, 70, 73, 78], five in Netherland 
[48, 61, 66, 77, 79], three each in both China [52, 65, 68] 
and Turkey [43, 46, 82], two each in Egypt [49, 76], Brazil 
[54, 81], and Italy [71, 83], and eight in other countries 
[42, 57–60, 64, 69, 80]. The median sample size was 180 
recruited participants, with the 21 being the lowest [58] 
and 2080 being the highest number of participants [61] 
(see Tables 2, 3).
Reference standard
We did not consider enrolment criteria, including objec-
tive criteria for suspicion of VAP, to be part of the refer-
ence standard. Out of the 44 included studies, 32 studies 
(72.7%) compared an index test with a sole microbiologi-
cal reference standard (see Table 2). One of these studies 
did not define which of the studied tests were considered 
index and which were considered reference [54]. Of the 
remaining 31 studies, culture of BAL fluid was most com-
monly used as the reference test, forming at least part of 
the reference standard in 26 (83.8%) studies [40, 41, 43, 
45, 48, 49, 51, 55–60, 63, 65–67, 69, 70, 73–77, 79, 82]. 
BAL culture alone was the sole reference standard in 18 
(58.1%) out of the 31 studies [40, 41, 43, 45, 49, 55, 56, 
Fig. 1 PRISMA systematic review flow chart. Adapted from: Moher et al. [96]
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Table 1 Quality assessment checklist scores
green tick = acceptable quality, red box = unacceptable quality
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58, 60, 63, 65, 69, 70, 73–76, 82]. Where used, the BAL 
culture threshold for positivity included > 10  CFU/mL 
[76], >  103 CFU/mL [56], >  104 CFU/mL [40, 41, 43, 49, 55, 
58, 60, 63, 65, 69, 70, 73–75, 82], and >  105 CFU/mL [45]. 
Three studies using BAL culture >  104 CFU/mL added an 
additional stipulation on BAL culture results: one requir-
ing correction of microbial growth for plasma to BAL 
urea ratio [55], one requiring that lavage was bilateral 
[40], and one specifying culture took place immediately 
after lavage [60]. BAL culture was used in combination 
with another criterion regarding assessment of BAL on 
an additional eight occasions out of the 26 using BAL 
(30.8%); five out of these eight (62.5%) BAL culture 
or > 2% lavage cells containing intracellular organisms 
[48, 66, 67, 77, 79], one out of the eight (12.5%) BAL cul-
ture or bronchial washings culture (>  105 CFU/mL) [59], 
and two out of the eight (11.1%) BAL culture or ETA cul-
ture (>  106  CFU/mL [51] or no threshold specified [57]. 
On the remaining five out of 31 (16.1%) occasions where 
BAL culture was not incorporated into the microbio-
logical reference standard, three studies used mini-BAL 
culture >  104  CFU/mL [46, 47, 50], one study used ETA 
culture >  106  CFU/mL [42]m, and one study used ETA 
culture >  104 CFU/mL [83], as sole reference standards.
Table 3 summarises the remaining 12/44 (27.2%) stud-
ies which compared an index test to a composite refer-
ence standard or clinical scoring system [44, 52, 53, 61, 
62, 64, 68, 71, 72, 78, 80, 81]. An iteration of the CDC 
VAP definition was used in two out of the 12 studies 
(16.7%), one using the 2008 iteration for surveillance of 
VAP [62] and one using the 2015 iteration for surveillance 
of VAP (80]. One additional study [64] used a composite 
reference standard almost identical to the 2008 iteration 
of the CDC VAP surveillance criteria. The 2008 itera-
tion of the CDC surveillance criteria does not include 
any microbiological assessment of respiratory samples, 
and non-culture methods or histopathology may sup-
plant microbiological culture in the 2010 and 2015 iter-
ations of the CDC surveillance criteria [28, 62, 85]. For 
the remaining nine studies; four out of the nine (44.4%) 
explicitly incorporated the clinical pulmonary infection 
score (CPIS) into a wider set of criteria [44, 53, 61, 81]. 
Seven out nine (77.8%) incorporated radiological assess-
ment [52, 53, 64, 68, 71, 72, 78], eight out of nine (88.9%) 
incorporated additional clinical signs and symptoms [44, 
52, 53, 61, 71, 72, 78, 81] either as part of an existing scor-
ing system such as CPIS or de novo, and all nine studies 
(100%) incorporated some microbiological assessment 
into the combined reference standard [44, 52, 53, 64, 
68, 71, 72, 78, 81]. In seven of those nine studies (77.8%) 
positive microbiology was a mandatory criterion for VAP 
diagnosis [44, 52, 53, 64, 71, 78, 81], and in two of those 
nine (22.2%), positive microbiological cultures were an 
optional criterion for VAP diagnosis [68, 72]. Amongst all 
included studies microbiological assessment did not form 
any part of the mandatory or optional criteria for VAP 
diagnosis in only two studies [62, 64], diagnosis of VAP 
included an optional microbiological assessment com-
ponent in another two studies (i.e. VAP diagnosis could 
be made without recourse to microbiological assess-
ment) [68, 72], and in 39 studies microbiological assess-
ment was the sole or a mandatory component [40–53, 
55–60, 63–71, 73–79, 81–83]. Four studies incorporated 
an optional histopathologic element into the reference 
standard [61, 68, 72, 80], but it was mandatory in none.
Out of all 44 included studies, 37 (84%) incorporate 
BAL in either the reference standard or index test [40–
51, 54–60, 63, 65–79, 81, 82]. Twenty two studies (50%) 
included a precise lavage procedure in the methodol-
ogy [40, 41, 43, 45, 48, 51, 55–58, 60, 63, 66–69, 71, 72, 
74–76, 82]. Of these, 14 described an initial discard of 
aspirated fluid, considered to be uninformative bronchial 
fluid [40, 41, 43, 51, 57, 58, 60, 63, 68, 69, 71, 72, 74, 82]. 
The median volume of instilled fluid used to generate 
the discarded fluid was 20 mL (range 20 mL to 50 mL). 
The median total volume of instilled fluid (including 
that intended for discard) was 150  mL (range 80  mL to 
200 mL).
Discussion
To the best of our knowledge, this is the first and most 
comprehensive systematic review aiming to evaluate the 
reference standard tests used to evaluate novel index tests 
for suspected VAP since the publication of Rea-Neto and 
colleagues systematic review of diagnostic methods in 
2008 [32]. We reviewed papers comparing a novel index 
test against a chosen reference standard to identify what 
reference standards have been used in diagnostic evalua-
tion research for VAP. To deliver a high-quality system-
atic review, we excluded papers with a high risk of bias 
and all papers included in this review fulfil at least 5 out 
of the 8 criteria we included from the CASP checklist.
The microbiological culture was the sole or a compo-
nent criterion in the vast majority of studies. Overall, 
the culture of BAL fluid was the most common refer-
ence standard, with the most common growth threshold 
being >  104 CFU/mL. This was occasionally used in com-
bination with another reference standard, such as the 
demonstration of BAL cells with intracellular organisms 
exceeding 2% of the total number of cells. Composite ref-
erence standards incorporating a variety of existing clini-
cal scores, existing surveillance definitions, radiological 
assessments, clinical parameters, and microbiological 
methods including culture were used in the remain-
ing studies. A large variation in practice, processes, and 
reference standards were detected, highlighting the 
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inconsistency in the current diagnosis of VAP and mak-
ing a meta-analysis of diagnostic accuracy challenging. 
Biological, clinical, and statistical heterogeneity makes 
comparisons across the different studies difficult and 
subjective. We display a variable and generally good qual-
ity of the papers, and the review provides an indication 
of what has been and is being done in this area globally 
with respect to the use of reference standard in the diag-
nostics of VAP. The line between composite criteria and 
a sole microbiological criterion was often blurred. Many 
studies in the sole microbiological criterion group had 
strict objective clinical and radiological enrolment crite-
ria. Where these criteria are applied pre-enrolment and 
therefore applied to both index tests and reference stand-
ards we have not incorporated them into a description of 
the reference standard.
A key question in diagnostic accuracy research when 
reference standards are imperfect is whether the refer-
ence standard used to assess novel diagnostics should be 
‘more inclusive’ (higher sensitivity, lower specificity) or 
‘less inclusive’ (lower sensitivity, higher specificity). Using 
microbiological criteria alone exhibits good face validity 
but risks missing cases of ‘true VAP’ or including false 
positives through contamination (although prior speci-
fication of clinically suspected VAP reduces this risk). 
Importantly, both possibilities are potentially strongly 
influenced by operator technique/expertise, especially 
for BAL; this contrasts with diagnostics reliant on blood 
sampling or imaging. BAL culture was the most com-
mon microbiological method found in this review. The 
use of BAL culture is potentially problematic for sev-
eral reasons. Firstly, in a recent systematic review, when 
compared to the reference standard of histopathological 
examination of lung tissue, BAL culture had a sensitivity 
of 71.1% and specificity of 79.6% [86] echoing previous 
findings that microbiological examination does not cor-
relate well with histopathological examination [32]. Sec-
ondly, the timing and nature of prior antibiotic therapy 
may adversely affect sample positivity [87, 88], although 
this problem is conceivably solved by incorporating a 
criterion addressing percentage of host cells contain-
ing invading organisms, a measure not affected by prior 
antibiotic therapy [75]. Thirdly, the BAL procedure itself 
is not standardised, and the requirements for sample 
collection are not uniform. Whilst this may have little 
impact on bacterial growth, a fact confirmed by one of 
the included studies [55], the variety of studies that uti-
lised bronchial discard may plausibly lead to a variety in 
sensitivity at detecting the causative pathogenic organ-
ism. Sole microbiological criteria also risk introducing 
cases of ‘false VAP’ through contamination [87], although 
this risk is reduced by using distal or protected speci-
mens. Of relevance, the quality and consistency of BAL 
procedures are likely to be higher in studies than during 
routine clinical practice, which could further influence its 
validity.
Using composite criteria may conceivably address the 
problem of missing cases of ‘true VAP’, and the number or 
thresholds of additional criteria is not limited. Additional 
criteria can be made mandatory to increase specificity 
or made optional to increase sensitivity. Some studies in 
this review rely on existing surveillance definitions for 
VAP or use their own composite standards. The exist-
ing surveillance definitions were designed to objectively 
and reproducibly monitor VAP rates not to identify true 
VAP in a robustly sensitive and specific manner, although 
as a quality indicator face validity amongst clinicians is 
important. Other composite studies incorporated radio-
logical assessments into the reference standard. It has 
been shown that chest x-ray changes are not considered 
integral to the diagnosis by many clinicians [89], that the 
performance characteristics of chest x-ray may not meet 
the requirements as a diagnostic standard [90–92], and 
that inter- and intra-observer variability is high in chest 
x-ray assessment [93, 94]. These issues mean that incor-
poration of radiology into any novel reference standard 
should be undertaken with caution. Many studies incor-
porate clinical signs which plausibly reduces the risk of 
false positives, and although this makes physiological 
sense there is minimal evidence to support this. Klompas 
et al. showed, in the development of the novel CDC VAP 
surveillance algorithm, that deterioration in oxygenation 
after a period of stability was associated with clinically 
important outcomes but the addition of other clinical 
measures such as abnormal temperature, abnormal white 
blood cell count, or purulent secretions was not [95]. 
However, a lack of correlation with clinically important 
outcomes is not the same as a lack of correlation with 
a true diagnosis of VAP; this issue is relevant when the 
decision based on the test relates to a therapy (antibiotic 
use) rather than prognosis.
No studies relied upon histopathological diagnosis of 
VAP to confirm the diagnosis. This is not surprising for 
practical reasons: it cannot be routinely and safely under-
taken in all patients with suspected VAP either at the 
time of the index test or later. Histopathological analysis 
may also be inaccurate due to sampling artefacts, the lack 
of representation of a small piece of tissue, and displace-
ment in time from the period of peak infection. It is not 
possible to provide certainty about the appropriate refer-
ence standard in diagnostic evaluation research for VAP 
following this systematic review, which simply identifies 
the methods chosen by researchers and confirms the lack 
of a standardised approach. Researchers must decide 
whether it is more important to be ‘more inclusive’ or 
‘less inclusive’, and future comparisons may wish to 
Page 16 of 19Al‑Omari et al. BMC Pulm Med          (2021) 21:196 
employ the strategy deployed by one of the studies in this 
review [61]: using a graded certainty of VAP from pos-
sible to probable to definite using a composite definition.
There are three main limitations to our review. Firstly, 
in order to be diagnosed with VAP, a patient must be 
at risk of VAP, and there is no standard definition for 
patients at risk. For the purposes of this study, we defined 
those at risk of VAP as those who have undergone more 
than 48  h of mechanical ventilation. Secondly, many 
included studies enrolled only patients with suspected 
VAP, and this means many listed reference standards 
must be prefixed with “clinically suspected VAP”. This 
level of clinical suspicion was not systematically collected 
by us. This is particularly noteworthy in considering the 
reference standards listed in Table  3. Thirdly, although 
data extraction for this review was completed before the 
impact of Coronavirus Disease 2019 (COVID-19), the 
pandemic nonetheless interfered with the delivery time 
of this review.
Conclusion
BAL culture with a microbiological growth threshold 
of >  104  CFU/mL is the commonest reference stand-
ard used to examine the utility of a novel index test for 
VAP amongst patients who are at risk for and clinically 
suspected of VAP. Composite reference standards were 
used in approximately 25% of reviewed studies. Nearly 
all reference standards for VAP identified in this review 
required some microbiological confirmation of infection. 
The studies identified in this review highlight the need 
for a standardised approach to diagnosis VAP which may 
include the development of a data-driven composite ref-
erence standard from large cohort studies.
Abbreviations
BAL: Broncho‑alveolar lavage; CDC: Centers for disease control and prevention; 
CC‑10: Clara cell protein 10; COVID‑19: Coronavirus Disease 2019; CASP: Critical 
appraisal skills programme; CBA: Cytometric bead array; ETA: Endotracheal 
aspirates; ECDC: European centre for disease prevention and control; GC‑tof‑
MS: Gas chromatography time‑of‑flight mass spectrometry; GS: Gram’s stain; 
ITU: Intensive therapy unite; LUS: Lung ultrasound; MeSH: Medical subject 
headings; CPIS: Modified clinical pulmonary infection score; NHSN/CDC: 
National healthcare safety network/Center for disease control and prevention; 
PCR: Polymerase chain reaction; PSB: Protected specimen brush; SQ: Semi 
quantitative; PCT: Serum procalcitonin; sTREM‑1: Type 1 soluble triggering 
receptor expressed on myeloid cells; U/S: Ultrasound; VAE: Ventilator‑asso‑
ciated events; VAP: Ventilator‑associated pneumonia; VOCs: Volatile organic 
compounds.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s12890‑ 021‑ 01560‑0.
Additional file 1. MEDLINE search example.




BA and AJA designed the review, and BA led the project. All authors con‑
tribute and approve the review design and search strategy. BA, PM, and JG 
conducted the title/abstract screening. The quality assessment and data 
extraction were conducted by BA, THC, PM, ARA, SG, JS, WSJ, BCL, AW, and MC. 
The data and results were summarized by BA, AJA, THC, SG, JS, WSJ, BCL, AW, 
MC, interpreted by THC and BA, reviewed by KD and TSW, and approved by 
all authors. The manuscript was drafted BA and THC, checked by KD and TSW 
and read and approved by all authors. All authors read and approved the final 
manuscript.
Funding
This study was funded by Combating Antibiotic‑Resistant Bacteria Biopharma‑
ceutical Accelerator (CARB‑X), https:// carb‑x. org, award Number 4500003353. 
AJA, JS, WJS, CL and AW were supported by the National Institute for Health 
Research Newcastle In Vitro Diagnostics Co‑operative. The views expressed 
are those of the author(s) and not necessarily those of the National Institute 
for Health Research, the National Health Services or the Department of Health 
and Social Care.
Availability of data and materials
The datasets used and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Declarations





The authors declare that they have no competing interests.
Author details
1 College of Medicine and Health Sciences, Khalifa University, PO Box 127788, 
Abu Dhabi, UAE. 2 School of Health and Life Science, University of Northum‑
bria, Newcastle upon Tyne, UK. 3 NIHR Newcastle In Vitro Diagnostics Co‑opera‑
tive, Translational and Clinical Research Institute, Newcastle University, New‑
castle upon Tyne, UK. 4 Translational Healthcare Technologies Group, Centre 
for Inflammation Research, Queen’s Medical Research Institute, University 
of Edinburgh, Edinburgh, UK. 5 York Health Economics Consortium, Enterprise 
House, Innovation Way, University of York, York, UK. 6 NIHR Newcastle In Vitro 
Diagnostics Co‑operative, The Newcastle Upon Tyne Hospitals NHS Founda‑
tion Trust, Newcastle upon Tyne, UK. 7 Laboratory Medicine, Newcastle‑Upon‑
Tyne Hospitals Foundation Trust, Newcastle upon Tyne, UK. 8 Edinburgh Critical 
Care Research Group, University of Edinburgh, Edinburgh, UK. 
Received: 11 March 2021   Accepted: 2 June 2021
References
 1. Craven TH, Wojcik G, McCoubrey J, Brooks O, Grant E, Keating S, et al. 
Ventilator‑associated pneumonia surveillance using two methods. J Hosp 
Infect. 2020;104(4):522–8.
 2. Fang X, Mei Q, Fan X, Zhu C, Yang T, Zhang L, et al. Diagnostic value of 
metagenomic next‑generation sequencing for the detection of patho‑
gens in bronchoalveolar lavage fluid in ventilator‑associated pneumonia 
patients. Front Microbiol. 2020;11:599756.
Page 17 of 19Al‑Omari et al. BMC Pulm Med          (2021) 21:196  
 3. Keyt H, Faverio P, Restrepo MI. Prevention of ventilator‑associated pneu‑
monia in the intensive care unit: a review of the clinically relevant recent 
advancements. Indian J Med Res. 2014;139(6):814–21.
 4. Steen J, Vansteelandt S, De Bus L, Depuydt P, Gadeyne B, Benoit DD, et al. 
Attributable mortality of ventilator‑associated pneumonia: replicating 
findings, revisiting methods. Ann Am Thorac Soc. 2020;18(5):830–7.
 5. Colombo SM, Palomeque AC, Li BG. The zero‑VAP sophistry and con‑
troversies surrounding prevention of ventilator‑associated pneumonia. 
Intensive Care Med. 2020;46(2):368–71.
 6. Keneally RJ, Peterson TJ, Benjamin JR, Hawkins K, Davison D. Making venti‑
lator associated pneumonia rate a meaningful quality marker. J Intensive 
Care Med. 2020. https:// doi. org/ 10. 1177/ 08850 66620 952763.
 7. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas‑Chanoin 
MH, et al. The prevalence of nosocomial infection in intensive care units 
in Europe. Results of the European Prevalence of Infection in Inten‑
sive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 
1995;274(8):639–44.
 8. Rello J, Ollendorf DA, Oster G, Vera‑Llonch M, Bellm L, Redman R, et al. 
Epidemiology and outcomes of ventilator‑associated pneumonia in a 
large US database. Chest. 2002;122(6):2115–21.
 9. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator‑
associated pneumonia in a large matched cohort. Infect Control Hosp 
Epidemiol. 2012;33(3):250–6.
 10. Luckraz H, Manga N, Senanayake EL, Abdelaziz M, Gopal S, Charman SC, 
et al. Cost of treating ventilator‑associated pneumonia post cardiac sur‑
gery in the National Health Service: Results from a propensity‑matched 
cohort study. J Intensive Care Soc. 2018;19(2):94–100.
 11. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Noso‑
comial pneumonia in ventilated patients: a cohort study evaluating 
attributable mortality and hospital stay. Am J Med. 1993;94(3):281–8.
 12. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun‑Buisson C. The attribut‑
able morbidity and mortality of ventilator‑associated pneumonia in the 
critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit 
Care Med. 1999;159(4 Pt 1):1249–56.
 13. Bekaert M, Timsit J‑F, Vansteelandt S, Depuydt P, Vésin A, Garrouste‑
Orgeas M, et al. Attributable mortality of ventilator‑associated pneu‑
monia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 
2011;184(10):1133–9.
 14. Ego A, Preiser J‑C, Vincent J‑L. Impact of diagnostic criteria on the inci‑
dence of ventilator‑associated pneumonia. Chest. 2015;147(2):347–55.
 15. Estella A, Alvarez‑Lerma F. Should the diagnosis of ventilator associated 
pneumonia be improved? Med Intensiva. 2011;35(9):578–82.
 16. Ali HS, Khan FY, George S, Shaikh N, Al‑Ajmi J. Epidemiology and outcome 
of ventilator‑associated pneumonia in a heterogeneous ICU population 
in Qatar. Biomed Res Int. 2016;2016:8231787.
 17. Papazian L, Klompas M, Luyt C‑E. Ventilator‑associated pneumonia in 
adults: a narrative review. Intensive Care Med. 2020;46(5):888–906.
 18. Skrupky LP, McConnell K, Dallas J, Kollef MH. A comparison of ventilator‑
associated pneumonia rates as identified according to the National 
Healthcare Safety Network and American College of Chest Physicians 
criteria. Crit Care Med. 2012;40(1):281–4.
 19. Hyllienmark P, Gårdlund B, Persson J‑O, Ekdahl K. Nosocomial pneu‑
monia in the ICU: a prospective cohort study. Scand J Infect Dis. 
2007;39(8):676–82.
 20. Tejerina E, Frutos‑Vivar F, Restrepo MI, Anzueto A, Abroug F, Palizas F, et al. 
Incidence, risk factors, and outcome of ventilator‑associated pneumonia. 
J Crit Care. 2006;21(1):56–65.
 21. Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, et al. Inci‑
dence of and risk factors for ventilator‑associated pneumonia in critically 
ill patients. Ann Intern Med. 1998;129(6):433–40.
 22. Kollef MH. Ventilator‑associated pneumonia. A multivariate analysis. 
JAMA. 1993;270(16):1965–70.
 23. Kappstein I, Schulgen G, Beyer U, Geiger K, Schumacher M, Daschner FD. 
Prolongation of hospital stay and extra costs due to ventilator‑associated 
pneumonia in an intensive care unit. Eur J Clin Microbiol Infect Dis. 
1992;11(6):504–8.
 24. Rello J, Quintana E, Ausina V, Castella J, Luquin M, Net A, et al. Incidence, 
etiology, and outcome of nosocomial pneumonia in mechanically venti‑
lated patients. Chest. 1991;100(2):439–44.
 25. Dudeck MA, Horan TC, Peterson KD, Allen‑Bridson K, Morrell G, Pollock 
DA, et al. National Healthcare Safety Network (NHSN) Report, data 
summary for 2010, device‑associated module. Am J Infect Control. 
2011;39(10):798–816.
 26. Suetens C, Morales I, Savey A, Palomar M, Hiesmayr M, Lepape A, et al. 
European surveillance of ICU‑acquired infections (HELICS‑ICU): methods 
and main results. J Hosp Infect. 2007;65(Suppl 2):171–3.
 27. De Bus L, Gadeyne B, Steen J, Boelens J, Claeys G, Benoit D, et al. A com‑
plete and multifaceted overview of antibiotic use and infection diagnosis 
in the intensive care unit: results from a prospective four‑year registration. 
Crit Care. 2018;22(1):241.
 28. Craven TH, Wojcik G, McCoubrey J, Brooks O, Grant E, Reilly J, et al. Lack of 
concordance between ECDC and CDC systems for surveillance of ventila‑
tor associated pneumonia. Intensive Care Med. 2018;44(2):265–6.
 29. Martin‑Loeches I, Torres A, Rinaudo M, Terraneo S, de Rosa F, Ram‑
irez P, et al. Resistance patterns and outcomes in intensive care unit 
(ICU)‑acquired pneumonia. Validation of European Centre for Disease 
Prevention and Control (ECDC) and the Centers for Disease Control and 
Prevention (CDC) classification of multidrug resistant organisms. J Infect. 
2015;70(3):213–22.
 30. Baselski V, Klutts JS, Baselski V, Klutts JS. Quantitative cultures of bron‑
choscopically obtained specimens should be performed for optimal 
management of ventilator‑associated pneumonia. J Clin Microbiol. 
2013;51(3):740–4.
 31. Torres A, Niederman MS, Chastre J, Ewig S, Fernandez‑Vandellos P, 
Hanberger H, et al. International ERS/ESICM/ESCMID/ALAT guidelines 
for the management of hospital‑acquired pneumonia and ventilator‑
associated pneumonia: Guidelines for the management of hospital‑
acquired pneumonia (HAP)/ventilator‑associated pneumonia (VAP) of 
the European Respiratory Society (ERS), European Society of Intensive 
Care Medicine (ESICM), European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax 
(ALAT). Eur Respir J. 2017;50(3):1700582. https:// doi. org/ 10. 1183/ 13993 
003. 00582‑ 2017.
 32. Rea‑Neto A, Youssef NCM, Tuche F, Brunkhorst F, Ranieri VM, Reinhart K, 
et al. Diagnosis of ventilator‑associated pneumonia: a systematic review 
of the literature. Crit Care. 2008;12(2):R56.
 33. Al‑Omari B, McMeekin P, Gray J, Aleen J, Dhaliwal K, Walsh T, et al. Protocol 
for systematic review of studies investigating ventilator‑associated 
pneumonia(VAP) diagnostic procedures in secondary care [Internet]. 
PROSPERO; CRD42019125449. 2019. https:// www. crd. york. ac. uk/ prosp 
ero/ displ ay_ record. php? Recor dID= 125449. Cited 24 Nov 2020.
 34. https:// casp‑ uk. net/ wp‑ conte nt/ uploa ds/ 2018/ 01/ CASP‑ Diagn ostic‑ 
Check list‑ 2018. pdf [Internet]. https:// casp‑ uk. net/ wp‑ conte nt/ uploa ds/ 
2018/ 01/ CASP‑ Diagn ostic‑ Check list‑ 2018. pdf. Cited 24 Nov 2020.
 35. Ma L‑L, Wang Y‑Y, Yang Z‑H, Huang D, Weng H, Zeng X‑T. Methodological 
quality (risk of bias) assessment tools for primary and secondary medical 
studies: what are they and which is better? Mil Med Res. 2020;7(1):7.
 36. Zeng X, Zhang Y, Kwong JSW, Zhang C, Li S, Sun F, et al. The methodologi‑
cal quality assessment tools for preclinical and clinical studies, systematic 
review and meta‑analysis, and clinical practice guideline: a systematic 
review. J Evid Based Med. 2015;8(1):2–10.
 37. Williams P, Bond CM, Burton C, Murchie P. A systematic review of the use, 
quality and effects of pelvic examination in primary care for the detection 
of gynaecological cancer. J Obstet Gynaecol. 2018;38(5):737.
 38. Gomes PTM, Lima LHL, Bueno MKG, Araújo LA, Souza NM. Autism in 
Brazil: a systematic review of family challenges and coping strategies. J 
Pediatr (Rio J). 2015;91(2):111–21.
 39. Smith T, Cross J, Poland F, Clay F, Brookes A, Maidment I, et al. Systematic 
review investigating multi‑disciplinary team approaches to screening 
and early diagnosis of dementia in primary care—what are the positive 
and negative effects and who should deliver it? Curr Alzheimer Res. 
2018;15(1):5–17.
 40. Jackson S‑R, Ernst NE, Mueller EW, Butler KL. Utility of bilateral bronchoal‑
veolar lavage for the diagnosis of ventilator‑associated pneumonia in 
critically ill surgical patients. Am J Surg. 2008;195(2):159–63.
 41. Hellyer TP, Morris AC, McAuley DF, Walsh TS, Anderson NH, Singh S, et al. 
Diagnostic accuracy of pulmonary host inflammatory mediators in the 
exclusion of ventilator‑acquired pneumonia. Thorax. 2015;70(1):41–7.
 42. Hashimoto S, Shime N. Evaluation of semi‑quantitative scoring of Gram 
staining or semi‑quantitative culture for the diagnosis of ventilator‑asso‑
ciated pneumonia: a retrospective comparison with quantitative culture. 
J Intensive Care. 2013;1(1):2.
Page 18 of 19Al‑Omari et al. BMC Pulm Med          (2021) 21:196 
 43. Guler E, Kahveci F, Akalin H, Sinirtas M, Bayram S, Ozcan B. Evaluation of 
a clinical pulmonary infection score in the diagnosis of ventilator‑associ‑
ated pneumonia. SV. 2012;7(1):32–7.
 44. Grover V, Pantelidis P, Soni N, Takata M, Shah PL, Wells AU, et al. A bio‑
marker panel (Bioscore) incorporating monocytic surface and soluble 
TREM‑1 has high discriminative value for ventilator‑associated pneumo‑
nia: a prospective observational study. PLoS ONE. 2014;9(10):e109686.
 45. Goldberg AE, Malhotra AK, Riaz OJ, Aboutanos MB, Duane TM, Borchers 
CT, et al. Predictive value of broncho‑alveolar lavage fluid Gram’s stain in 
the diagnosis of ventilator‑associated pneumonia: a prospective study. J 
Trauma. 2008;65(4):871–6 (discussion 876).
 46. Gedik H, Yahyaoğlu M, Fincancı M. The diagnostic accuracy of endotra‑
cheal aspiration and mini‑bronchoalveolar lavage cultures in the diagno‑
sis of ventilator associated pneumonia. Nobel Med. 2010;6:68–74.
 47. Fujitani S, Cohen‑Melamed MH, Tuttle RP, Delgado E, Taira Y, Darby JM. 
Comparison of semi‑quantitative endotracheal aspirates to quantitative 
non‑bronchoscopic bronchoalveolar lavage in diagnosing ventilator‑
associated pneumonia. Respir Care. 2009;54(11):1453–61.
 48. Schnabel R, Fijten R, Smolinska A, Dallinga J, Boumans M‑L, Stobberingh 
E, et al. Analysis of volatile organic compounds in exhaled breath to 
diagnose ventilator‑associated pneumonia. Sci Rep. 2015;5:17179.
 49. Elmahalawy II, Ammar AS, Fathy WM, Salama AE, Mokhtar WS. Pentraxin 3 
as an early marker in diagnosis of ventilator associated pneumonia. Egypt 
J Chest Dis Tuberc. 2017;66(4):709–12.
 50. Douglas IS, Price CS, Overdier KH, Wolken RF, Metzger SW, Hance 
KR, et al. Rapid automated microscopy for microbiological surveil‑
lance of ventilator‑associated pneumonia. Am J Respir Crit Care Med. 
2015;191(5):566–73.
 51. Clavel M, Barraud O, Moucadel V, Meynier F, Karam E, Ploy MC, et al. 
Molecular quantification of bacteria from respiratory samples in patients 
with suspected ventilator‑associated pneumonia. Clin Microbiol Infect. 
2016;22(9):812.e1‑812.e7.
 52. Chen C, Yan M, Hu C, Lv X, Zhang H, Chen S. Diagnostic efficacy of serum 
procalcitonin, C‑reactive protein concentration and clinical pulmonary 
infection score in Ventilator‑Associated Pneumonia. Med Sci (Paris). 
2018;34((Focus issue F1)):26–32.
 53. Charles PE, Kus E, Aho S, Prin S, Doise J‑M, Olsson N‑O, et al. Serum procal‑
citonin for the early recognition of nosocomial infection in the critically ill 
patients: a preliminary report. BMC Infect Dis. 2009;9:49.
 54. de Carvalho EM, Massarollo PCB, Levin AS, Isern MRM, Pereira WL, Abdala 
E, et al. Comparative study of etiological diagnosis of nosocomial pneu‑
monia. Braz J Infect Dis. 2008;12(1):67–74.
 55. Baldesi O, Michel F, Guervilly C, Embriaco N, Granfond A, La Scola B, et al. 
Bacterial ventilator‑associated pneumonia: bronchoalveolar lavage results 
are not influenced by dilution. Intensive Care Med. 2009;35(7):1210–5.
 56. Anand NJ, Zuick S, Klesney‑Tait J, Kollef MH. Diagnostic implications of 
soluble triggering receptor expressed on myeloid cells‑1 in BAL fluid of 
patients with pulmonary infiltrates in the ICU. Chest. 2009;135(3):641–7.
 57. Albert M, Friedrich JO, Adhikari NKJ, Day AG, Verdant C, Heyland DK, et al. 
Utility of Gram stain in the clinical management of suspected ventilator‑
associated pneumonia. Secondary analysis of a multicenter randomized 
trial. J Crit Care. 2008;23(1):74–81.
 58. Leo A, Galindo‑Galindo J, Folch E, Guerrero A, Bosques F, Mercado R, et al. 
Comparison of bronchoscopic bronchoalveolar lavage vs blind lavage 
with a modified nasogastric tube in the etiologic diagnosis of ventilator‑
associated pneumonia. Med Intensiva. 2008;32(3):115–20.
 59. Kwon S‑J, Jeon T, Seo D, Na M, Choi E‑G, Son J‑W, et al. Quantitative 
PCR for etiologic diagnosis of methicillin‑resistant Staphylococcus 
aureus pneumonia in Intensive Care Unit. Tuberc Respir Dis (Seoul). 
2012;72(3):293–301.
 60. Kneidinger N, Warszawska J, Schenk P, Fuhrmann V, Bojic A, Hirschl A, 
et al. Storage of bronchoalveolar lavage fluid and accuracy of microbio‑
logic diagnostics in the ICU: a prospective observational study. Crit Care. 
2013;17(4):R135.
 61. Klein Klouwenberg PMC, van Mourik MSM, Ong DSY, Horn J, Schultz 
MJ, Cremer OL, et al. Electronic implementation of a novel surveillance 
paradigm for ventilator‑associated events. Feasibility and validation. Am J 
Respir Crit Care Med. 2014;189(8):947–55.
 62. Klompas M, Kleinman K, Platt R. Development of an algorithm for 
surveillance of ventilator‑associated pneumonia with electronic data and 
comparison of algorithm results with clinician diagnoses. Infect Control 
Hosp Epidemiol. 2008;29(1):31–7.
 63. Jung B, Embriaco N, Roux F, Forel J‑M, Demory D, Allardet‑Servent J, et al. 
Microbiogical data, but not procalcitonin improve the accuracy of the 
clinical pulmonary infection score. Intensive Care Med. 2010;36(5):790–8.
 64. Jovanovic B, Djuric O, Markovic‑Denic L, Isakovic A, Doklestic K, Stankovic 
S, et al. Prognostic value of presepsin (soluble CD14‑subtype) in diagnosis 
of ventilator‑associated pneumonia and sepsis in trauma patients. VSP. 
2018;75(10):968–77.
 65. Jiao J, Wang M, Zhang J, Shen K, Liao X, Zhou X. Procalcitonin as a 
diagnostic marker of ventilator‑associated pneumonia in cardiac surgery 
patients. Exp Ther Med. 2015;9(3):1051–7.
 66. Oudhuis GJ, Beuving J, Bergmans D, Stobberingh EE, ten Velde G, Linssen 
CF, et al. Soluble Triggering Receptor Expressed on Myeloid cells‑1 in 
bronchoalveolar lavage fluid is not predictive for ventilator‑associated 
pneumonia. Intensive Care Med. 2009;35(7):1265–70.
 67. Linssen CFM, Bekers O, Drent M, Jacobs JA. C‑reactive protein and proc‑
alcitonin concentrations in bronchoalveolar lavage fluid as a predictor of 
ventilator‑associated pneumonia. Ann Clin Biochem. 2008;45(Pt 3):293–8.
 68. Liu C, Du Z, Zhou Q, Hu B, Li Z, Yu L, et al. Microscopic examination of 
intracellular organisms in bronchoalveolar lavage fluid for the diagnosis 
of ventilator‑associated pneumonia: a prospective multi‑center study. 
Chin Med J. 2014;127(10):1808–13.
 69. Luna CM, Sarquis S, Niederman MS, Sosa FA, Otaola M, Bailleau N, et al. 
Is a strategy based on routine endotracheal cultures the best way 
to prescribe antibiotics in ventilator‑associated pneumonia? Chest. 
2013;144(1):63–71.
 70. Luyt C‑E, Combes A, Reynaud C, Hekimian G, Nieszkowska A, Tonnellier M, 
et al. Usefulness of procalcitonin for the diagnosis of ventilator‑associated 
pneumonia. Intensive Care Med. 2008;34(8):1434–40.
 71. Mauri T, Coppadoro A, Bombino M, Bellani G, Zambelli V, Fornari C, et al. 
Alveolar pentraxin 3 as an early marker of microbiologically confirmed 
pneumonia: a threshold‑finding prospective observational study. Crit 
Care. 2014;18(5):562.
 72. Medford ARL, Husain SA, Turki HM, Millar AB. Diagnosis of ventilator‑
associated pneumonia. J Crit Care. 2009;24(3):473.e1‑6.
 73. Mongodi S, Via G, Girard M, Rouquette I, Misset B, Braschi A, et al. Lung 
ultrasound for early diagnosis of ventilator‑associated pneumonia. Chest. 
2016;149(4):969–80.
 74. Conway Morris A, Kefala K, Wilkinson TS, Moncayo‑Nieto OL, Dhaliwal 
K, Farrell L, et al. Diagnostic importance of pulmonary interleukin‑
1beta and interleukin‑8 in ventilator‑associated pneumonia. Thorax. 
2010;65(3):201–7.
 75. Linssen CFM, Jacobs JA, Schouten JSAG, van Mook WNKA, Ramsay G, 
Drent M. Influence of antibiotic therapy on the cytological diagnosis of 
ventilator‑associated pneumonia. Intensive Care Med. 2008;34(5):865–72.
 76. Refaat A, Affara N, Abdel‑fatah W, Hussein T, El‑gerbi M. Diagnostic 
accuracy of inflammatory biomarkers in bronchoalveolar lavage from 
patients with ventilator‑associated pneumonia. Egypt J Chest Dis Tuberc. 
2014;63(3):723–30.
 77. Scholte JBJ, van Dessel HA, Linssen CFM, Bergmans DCJJ, Savelkoul 
PHM, Roekaerts PMHJ, et al. Endotracheal aspirate and bronchoalveolar 
lavage fluid analysis: interchangeable diagnostic modalities in suspected 
ventilator‑associated pneumonia? J Clin Microbiol. 2014;52(10):3597–604.
 78. Textoris J, Loriod B, Benayoun L, Gourraud P‑A, Puthier D, Albanèse J, 
et al. An evaluation of the role of gene expression in the prediction 
and diagnosis of ventilator‑associated pneumonia. Anesthesiology. 
2011;115(2):344–52.
 79. Vanspauwen MJ, Linssen CFM, Bruggeman CA, Jacobs JA, Drent M, 
Bergmans DCJJ, et al. Clara cell protein in bronchoalveolar lavage fluid: a 
predictor of ventilator‑associated pneumonia? Crit Care. 2011;15(1):R14.
 80. Vernikos P, Kampolis CF, Konstantopoulos K, Armaganidis A, Karakitsos 
P. The role of bronchoscopic findings and bronchoalveolar lavage fluid 
cytology in early diagnosis of ventilator‑associated pneumonia. Respir 
Care. 2016;61(5):658–67.
 81. Waltrick R, Possamai DS, de Aguiar FP, Dadam M, de Souza Filho VJ, Ramos 
LR, et al. Comparison between a clinical diagnosis method and the sur‑
veillance technique of the Center for Disease Control and Prevention for 
identification of mechanical ventilator‑associated pneumonia. Rev Bras 
Ter Intensiva. 2015;27(3):260–5.
Page 19 of 19Al‑Omari et al. BMC Pulm Med          (2021) 21:196  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 82. Yagmurdur H, Tezcan AH, Karakurt O, Leblebici F. The efficiency of routine 
endotracheal aspirate cultures compared to bronchoalveolar lavage 
cultures in ventilator‑associated pneumonia diagnosis. Niger J Clin Pract. 
2016;19(1):46–51.
 83. Zagli G, Cozzolino M, Terreni A, Biagioli T, Caldini AL, Peris A. Diagnosis 
of ventilator‑associated pneumonia: a pilot, exploratory analysis of 
a new score based on procalcitonin and chest echography. Chest. 
2014;146(6):1578–85.
 84. Umemneku Chikere CM, Wilson K, Graziadio S, Vale L, Allen AJ. Diagnostic 
test evaluation methodology: a systematic review of methods employed 
to evaluate diagnostic tests in the absence of gold standard—an update. 
PLoS ONE. 2019;14(10):e0223832.
 85. Lalwani S, Mathur P, Tak V, Janani S, Kumar SI, Bagla R, et al. Diagnosis of 
ventilator‑associated pneumonia: comparison between ante‑mortem 
and post‑mortem cultures in trauma patients. Indian J Med Microbiol. 
2014;32(3):294–300.
 86. Fernando SM, Tran A, Cheng W, Klompas M, Kyeremanteng K, Mehta S, 
et al. Diagnosis of ventilator‑associated pneumonia in critically ill adult 
patients‑a systematic review and meta‑analysis. Intensive Care Med. 
2020;46(6):1170–9.
 87. Morris AC, Kefala K, Simpson AJ, Wilkinson TS, Everingham K, Kerslake D, 
et al. Evaluation of the effect of diagnostic methodology on the reported 
incidence of ventilator‑associated pneumonia. Thorax. 2009;64(6):516–22.
 88. Kamel T, Helms J, Janssen‑Langenstein R, Kouatchet A, Guillon A, 
Bourenne J, et al. Benefit‑to‑risk balance of bronchoalveolar lavage in the 
critically ill. A prospective, multicenter cohort study. Intensive Care Med. 
2020;46(3):463–74.
 89. Browne E, Hellyer TP, Baudouin SV, Conway Morris A, Linnett V, McAuley 
DF, et al. A national survey of the diagnosis and management of 
suspected ventilator‑associated pneumonia. BMJ Open Respir Res. 
2014;1(1):e000066.
 90. Butler KL, Sinclair KE, Henderson VJ, McKinney G, Mesidor DA, Katon‑
Benitez I, et al. The chest radiograph in critically ill surgical patients is 
inaccurate in predicting ventilator‑associated pneumonia. Am Surg. 
1999;65(9):805–9 (discussion 809).
 91. Wunderink RG, Woldenberg LS, Zeiss J, Day CM, Ciemins J, Lacher DA. The 
radiologic diagnosis of autopsy‑proven ventilator‑associated pneumonia. 
Chest. 1992;101(2):458–63.
 92. Lefcoe MS, Fox GA, Leasa DJ, Sparrow RK, McCormack DG. Accu‑
racy of portable chest radiography in the critical care setting. Chest. 
1994;105(3):885–7.
 93. Beards SC, Jackson A, Hunt L, Wood A, Frerk CM, Brear G, et al. Interob‑
server variation in the chest radiograph component of the lung injury 
score. Anaesthesia. 1995;50(11):928–32.
 94. Rubenfeld GD, Caldwell E, Granton J, Hudson LD, Matthay MA. Interob‑
server variability in applying a radiographic definition for ARDS. Chest. 
1999;116(5):1347–53.
 95. Klompas M, Magill S, Robicsek A, Strymish JM, Kleinman K, Evans RS, et al. 
Objective surveillance definitions for ventilator‑associated pneumonia. 
Crit Care Med. 2012;40(12):3154–61.
 96. Moher D, Liberati A, Tatzlaff J, Altman DG, The PRISMA Group. Preferred 
reporting items for systematic reviews and meta‑analyses: the PRISMA 
statement. PLos Med. 2009; 6(6):e1000097. https:// doi. org/ 10. 1371/ journ 
al. pmed1 000097
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
